ライフサイエンスコーパス: abiraterone acetate

1 CS, TTS, and TTR compared with initiation of abiraterone acetate.

2 tory potential include dihydroergotamine and abiraterone acetate.

3 l patients who received at least one dose of abiraterone acetate.

4 ecline in CTCs after starting treatment with abiraterone acetate.

5 this multicenter, two-stage, phase II study, abiraterone acetate 1,000 mg was administered once daily

6 Patients received oral abiraterone acetate (1 g) once daily and prednisone (5 m

7 from Dec 17, 2015) or standard of care plus abiraterone acetate 1000 mg and prednisolone 5 mg (in th

8 oral apalutamide 240 mg once daily plus oral abiraterone acetate 1000 mg once daily and oral predniso

9 patients were also scheduled to receive oral abiraterone acetate 1000 mg once daily plus oral prednis

10 a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5

11 Participants received oral doses of abiraterone acetate (1000 mg daily) and prednisone (5 mg

12 onse system in a 1:1 ratio to receive either abiraterone acetate (1000 mg once daily) plus prednisone

13 ents were randomly assigned (1:1) to receive abiraterone acetate (1000 mg) once daily orally plus pre

14 e randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twic

15 Abiraterone acetate, 1000 mg, once daily by mouth with p

16 Abiraterone acetate, 1000 mg, once daily with prednisone

17 rednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patie

18 In the past year abiraterone acetate, a CYP17 (17alpha-hydroxylase/17, 20

19 with overexpressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks ster

20 Abiraterone acetate (AA) is a potent and selective inhib

21 In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged o

22 not reduce serum androgens as effectively as abiraterone acetate (AA), a prodrug of abiraterone, a CY

23 Abiraterone acetate (ABI) and enzalutamide (ENZ) are con

24 en receptor signaling inhibitors (ARSi) like abiraterone acetate (Abi) and enzalutamide (Enza) or a f

25 This is the first evidence that abiraterone acetate achieves sustained suppression of te

26 were administered concurrently compared with abiraterone acetate alone (interaction HR 1.02, 0.70-1.5

27 Journal of Medicine describe the utility of abiraterone acetate, an androgen biosynthesis inhibitor,

28 Abiraterone acetate, an androgen biosynthesis inhibitor,

29 We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthes

30 al was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inh

31 A third agent, abiraterone acetate, an orally administered CYP17 inhibi

32 meta-analysis, as add-on treatments to ADT, abiraterone acetate and apalutamide may provide the larg

33 ls of novel hormonal agents, with a focus on abiraterone acetate and enzalutamide (MDV3100).

34 Abiraterone acetate and enzalutamide are recommended as

35 t of novel anti-androgen therapies including abiraterone acetate and enzalutamide.

36 rmone agonists and antagonists, or with oral abiraterone acetate and oral prednisolone (5 mg daily; c

37 Phase III data with abiraterone acetate and phase II data with MDV-3100, alo

38 ed: none in the control groups, three in the abiraterone acetate and prednisolone group (one event ea

39 ne 5 mg (in the abiraterone trial) orally or abiraterone acetate and prednisolone plus enzalutamide 1

40 and a respiratory disorder), and four in the abiraterone acetate and prednisolone with enzalutamide g

41 sought to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide

42 , a potent and specific PARP inhibitor, with abiraterone acetate and prednisone (AAP) versus placebo

43 PC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone (AAP), apalutamide (A

44 from first-line therapy with niraparib plus abiraterone acetate and prednisone (AAP).

45 biraterone-prednisone group) or placebo plus abiraterone acetate and prednisone (abiraterone-predniso

46 te cancer previously treated with docetaxel, abiraterone acetate and prednisone offer significant ben

47 group were allowed to cross over to receive abiraterone acetate and prednisone plus ADT treatment as

48 ith clinically significant pain at baseline, abiraterone acetate and prednisone resulted in significa

49 7]; p=0.0056) were significantly better with abiraterone acetate and prednisone than with prednisone

50 -related event was significantly longer with abiraterone acetate and prednisone than with prednisone

51 care treatment options such as enzalutamide, abiraterone acetate, and docetaxel after ADT.

52 el CYP17 inhibitors, including ketoconazole, abiraterone acetate, and VN/124-1, which are agents curr

53 s with 7287 patients comparing 6 treatments (abiraterone acetate, apalutamide, docetaxel, enzalutamid

54 trials evaluating the addition of docetaxel, abiraterone acetate, apalutamide, or enzalutamide to and

55 Randomized, phase III trials of abiraterone acetate are underway to define the future ro

56 We investigated the activity of abiraterone acetate as second-line treatment in ADT-resi

57 n, development of sustained side-effects, or abiraterone acetate becoming available in the respective

58 for these patients have expanded to include abiraterone acetate, cabazitaxel and enzalutamide.

59 icantly longer OS compared with those in the abiraterone acetate cohort (31.8 vs 23.0 months; hazard

60 shorter time to first SRE compared with the abiraterone acetate cohort (32.4 vs 42.7 months; HR, 1.2

61 d abiraterone acetate with prednisone alone (abiraterone acetate cohort), and 216 men (29.0%) receive

62 Fasted or fed cohorts received abiraterone acetate doses of 250, 500, 750, or 1,000 mg

63 combination treatment using apalutamide plus abiraterone acetate, each of which suppresses the androg

64 ancer starting any treatment with docetaxel, abiraterone acetate, enzalutamide, or radium Ra 223 dich

65 The development of cabazitaxel, abiraterone acetate, enzalutamide, radium-223, and sipul

66 This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics,

67 n this early-access protocol trial to assess abiraterone acetate for patients with metastatic castrat

68 n observed: 354 (65%) of 546 patients in the abiraterone acetate group and 387 (71%) of 542 in the pl

69 Overall, 365 (67%) patients in the abiraterone acetate group and 435 (80%) in the placebo g

70 all survival was significantly longer in the abiraterone acetate group than in the placebo group (34.

71 ac disorders (41 [8%] of 542 patients in the abiraterone acetate group vs 20 [4%] of 540 patients in

72 ce daily) plus prednisone (5 mg twice daily; abiraterone acetate group) or placebo plus prednisone (p

73 Abiraterone acetate has significant antitumor activity i

74 overall survival when added to ADT included abiraterone acetate (hazard ratio [HR], 0.61; 95% credib

75 , apalutamide (HR, 0.48; 95% CI, 0.39-0.60), abiraterone acetate (HR, 0.51; 95% CI, 0.45-0.58), and d

76 her support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive

77 01 to enable worldwide preapproval access to abiraterone acetate in patients with metastatic castrati

78 Abiraterone acetate is a first-line therapy for castrati

79 Abiraterone acetate is a prodrug of abiraterone, a selec

80 Abiraterone acetate is an effective treatment for metast

81 or men with metastatic CRPC, and approval of abiraterone acetate is anticipated based on the results

82 ncer (mCRPC) patients in a phase II study of abiraterone acetate (NCT01867710) were subjected to cust

83 characteristics between patients initiating abiraterone acetate or enzalutamide and evaluated restri

84 lth care system who initiated treatment with abiraterone acetate or enzalutamide between January 1, 2

85 (P = 0.020) increase in expression following abiraterone acetate or enzalutamide therapy.

86 Receipt of abiraterone acetate or enzalutamide.

87 ceptor pathway inhibitors (ARPIs), including abiraterone acetate or enzalutamide.

88 trol (docetaxel or a second-generation ARPI [abiraterone acetate or enzalutamide]).

89 el does not support use of either micronized abiraterone acetate or the 250 mg dose of abiraterone wi

90 Abiraterone acetate plus prednisolone (herein referred t

91 Abiraterone acetate plus prednisolone improves survival

92 tamide, an androgen receptor antagonist, and abiraterone acetate plus prednisone (AAP) prolong surviv

93 (6.2%) on enzalutamide + ADT, 1262 (5.6%) on abiraterone acetate plus prednisone + ADT, and 11,961 (5

94 nt long-term survival outcomes and safety of abiraterone acetate plus prednisone and ADT from the fin

95 The abiraterone acetate plus prednisone and prednisone-alone

96 These findings support the use of abiraterone acetate plus prednisone as a standard of car

97 iving prednisone alone subsequently received abiraterone acetate plus prednisone as crossover per pro

98 occurred in three (<1%) patients each in the abiraterone acetate plus prednisone group (gastric ulcer

99 all survival was significantly longer in the abiraterone acetate plus prednisone group (median 53.3 m

100 atients were randomly assigned to either the abiraterone acetate plus prednisone group (n=597) or pla

101 7.0) and 618 deaths (275 [46%] of 597 in the abiraterone acetate plus prednisone group and 343 [57%]

102 was hypokalaemia (four [1%] patients in the abiraterone acetate plus prednisone group and none in th

103 e events were hypertension (125 [21%] in the abiraterone acetate plus prednisone group vs 60 [10%] in

104 prednisone (5 mg) once daily orally and ADT (abiraterone acetate plus prednisone group) or matching p

105 occurred in 192 (32%) of 597 patients in the abiraterone acetate plus prednisone group, 151 (25%) of

106 alysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival,

107 Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP

108 We assessed concurrent treatment with abiraterone acetate plus prednisone or prednisolone and

109 The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did

110 Abiraterone acetate plus prednisone or prednisolone impr

111 se system-interactive web response system to abiraterone acetate plus prednisone or prednisolone with

112 23 (n=401) or placebo (n=405) in addition to abiraterone acetate plus prednisone or prednisolone.

113 Abiraterone acetate plus prednisone significantly improv

114 Abiraterone acetate plus prednisone significantly improv

115 al analysis of the phase 3 COU-AA-301 study, abiraterone acetate plus prednisone significantly prolon

116 lyses of the LATITUDE study, the addition of abiraterone acetate plus prednisone to androgen deprivat

117 the randomised, phase 3 COU-AA-301 trial of abiraterone acetate plus prednisone versus placebo plus

118 he individual-patient level in this trial of abiraterone acetate plus prednisone versus prednisone al

119 randomized, double-blind phase III trial of abiraterone acetate plus prednisone versus prednisone al

120 The combination of abiraterone acetate plus prednisone with ADT was associa

121 72 patients who crossed over from placebo to abiraterone acetate plus prednisone) and hypokalaemia (7

122 ng/mL or lower within 12 months of starting abiraterone acetate plus prednisone.

123 Abiraterone acetate potently disrupts intracrine androge

124 In the PEACE-1 trial (abiraterone acetate + prednisone), the HRs were 0.75 (95

125 8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo

126 alemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo

127 phase II randomized noncomparative trial of abiraterone acetate/prednisone (AAP) or AAP and cabazita

128 , and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium

129 Abiraterone acetate/prednisone, enzalutamide, or (223)Ra

130 The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among pat

131 llow-up of more than 4 years, treatment with abiraterone acetate prolonged overall survival compared

132 5%) of the 40 received PRO-related labeling (abiraterone acetate, ruxolitinib phosphate, and crizotin

133 d to ascertain the most effective regimen of abiraterone acetate to optimise patients' outcomes.

134 Abiraterone acetate was well tolerated and demonstrated

135 Abiraterone acetate was well tolerated.

136 etatasis-free survival when enzalutamide and abiraterone acetate were administered concurrently compa

137 Abiraterone acetate with prednisolone should be consider

138 ed in the analysis, 529 men (71.0%) received abiraterone acetate with prednisone alone (abiraterone a

139 745 consecutive patients who began receiving abiraterone acetate with prednisone as first-line therap

140 In this study, the addition of BRIs to abiraterone acetate with prednisone as first-line therap

141 est that the use of BRIs in combination with abiraterone acetate with prednisone as first-line therap

142 To determine the efficacy of abiraterone acetate with prednisone in these high-risk p

143 e clinical impact of the addition of BRIs to abiraterone acetate with prednisone in this disease sett

144 Abiraterone acetate with prednisone is currently the mos

145 cetate cohort), and 216 men (29.0%) received abiraterone acetate with prednisone plus BRIs (BRI cohor

146 [CHAARTED] E3805 study) at the initiation of abiraterone acetate with prednisone therapy.

147 Es (odds ratio, 23.72; 95% CI, 13.37-45.15), abiraterone acetate with slightly increased SAEs (odds r

148 average had longer OS than those initiating abiraterone acetate, with RMSTs of 24.29 months (95% CI,